CombiMatrix

GenScript believes that CustomArray's oligonucleotide synthesis and microarray manufacturing technology will enable it to better serve its customers.

Invitae issued approximately $21.2 million in shares of its own common stock to former CombiMatrix shareholders. 

The revenue increase was driven by higher test volumes in its reproductive health segment and improved test reimbursement across all segments.

The release of the financial results comes just days after molecular diagnostics firm Invitae announced it will acquire CombiMatrix.

Invitae is interested in companies that can contribute positively to its revenues in the next two to three quarters, according to CEO Sean George. 

The acquisitions will enable Invitae to add reproductive health genetic testing to its portfolio and become what it calls a "comprehensive genomic information company." 

The firm noted that its reproductive health test sales were up 32 percent year over year to $2.9 million, while volume for such tests were up 15 percent.

The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.

The company can now market the test in New York, in addition to other areas of the country where it has already made the assay available.

The firm reported 29 percent growth in its overall testing revenues, driven mainly by higher reproductive test volume and higher per-test revenue.

Pages

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.